Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

@article{Klink2008RituximabAI,
  title={Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development},
  author={Daniel Klink and Ruurd M. van Elburg and Marco W J Schreurs and Gijs Th J. van Well},
  journal={Clinical and Developmental Immunology},
  year={2008},
  volume={2008},
  pages={282 - 305}
}
We describe the effect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura (ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy. One month after the last rituximab administration a healthy girl was born. She had normal growth and development during the first six months. At birth, B-lymphocytes were not detectable. Rituximab levels in mother and neonate were 24000 and 6700 ng/mL… CONTINUE READING